MLR review is the cross-functional review that every piece of pharma promotional content goes through before it can be used. Medical checks that the science is accurate and supported, Legal checks the legal and liability risk, and Regulatory checks that the content is consistent with the approved labeling and with the rules that govern promotion. Some companies call the same group the PRC, for promotional review committee, or simply the review committee. Whatever the name, it is the gate between a draft and the market.
It is also, for most brand teams, the single biggest source of delay. That is rarely because reviewers are slow. It is because assets reach them in a state that forces another round. This guide walks through the process step by step, what each reviewer is actually looking for, the most common reasons content gets sent back, and the operating changes that reduce review cycles without asking anyone to lower the bar.
What does MLR stand for, and what does each reviewer check?
MLR stands for medical, legal and regulatory. Each function reads the same asset with a different question in mind, which is why a piece can pass one reviewer comfortably and stall with another.
The medical reviewer asks whether the content is scientifically accurate and fairly represents the evidence. They check that every claim is supported by its reference as worded, that data are presented with the right context (the study population, the endpoint, whether a result was primary or secondary), that statistics are not overstated, and that the overall picture matches what the clinical evidence shows.
The legal reviewer asks whether the content creates risk for the company. That covers misleading or unsubstantiated claims, comparative and superiority claims, use of trademarks and copyrighted material, testimonials and patient stories, consent for images and voices, and anything that could be read as an inducement to prescribe.
The regulatory reviewer asks whether the content complies with the rules for promotion in its market. In the US that means consistency with the FDA-approved prescribing information, fair balance between benefit and risk, the required safety information, the correct indication language, and the submission obligations that follow approval. Outside the US the same role applies local codes and regulations, such as the ABPI Code in the UK.
Around the reviewers sit the people who make the process run: the brand or content owner who submits the asset and answers comments, the agency that produces it, and often an MLR coordinator who manages the queue, the meeting agenda and the records.
The MLR review process, step by step
Most companies run some version of the same sequence. It starts with the brief, which should define the audience, the channel, the market and, most importantly, the claims the asset will make. Briefs that leave claim selection to the copywriter are the first cause of downstream rework.
The draft is then written with references attached. Every claim in the asset is linked to the specific page, table or figure in its source that supports it, usually with the supporting passage highlighted. This step, often called annotation or referencing, is where review time is saved or lost: a reviewer who has to hunt for support will send the asset back.
The asset is submitted into the review system, which for many companies is Veeva PromoMats, along with metadata describing its audience, channel, market and intended use. Reviewers comment, either asynchronously or in a scheduled review meeting, and the asset is approved, approved with changes, or returned for revision. Most assets go through more than one round.
After approval of the content, many companies run a final check on the rendered piece, the exact file, video or page that will go out, to confirm that what was approved is what will be used. In the US, promotional materials are then submitted to FDA on Form FDA 2253 at the time of first use. The asset carries an expiry or review date, and it must be withdrawn or updated when the label changes.
How long does MLR review take?
There is no single answer, because review time depends far more on the asset than on the reviewers. A reuse of approved content in a familiar format can clear in days. A new claim, a new format, a launch asset or anything with comparative data can take weeks. What drives the total is the number of rounds, not the time spent reading in each round.
That is why the most useful metric for an MLR process is not average days to approval. It is the first-pass approval rate: the share of assets approved, with or without minor changes, in their first round. A low first-pass rate means the process is spending reviewer time on problems that could have been caught before submission.
Track two more numbers alongside it: rounds per asset and the reasons assets are returned. Once you can see that a third of returns are for missing or weak references, or that one channel consistently comes back for fair balance, you know exactly where to fix the process upstream.
Why do assets get sent back in MLR review?
The most common reason is a claim that the reference does not support as worded. A study showing that a drug reduced an outcome in a specific population does not support a headline saying the drug reduces that outcome in general. Small changes in wording, such as “reduces” against “reduced”, “may” against “will”, or a dropped qualifier, are enough to change a claim's meaning.
The second is missing or underweighted safety information. Risk information that is present but smaller, later or harder to read than the benefit claims fails the fair balance test even when every word is correct. Reviewers judge the overall impression of the asset, not just whether the required text exists somewhere in it.
Other frequent causes include indication language that does not match the label, comparative claims without head-to-head evidence, visuals that imply benefits the data do not show, statistics presented without context, and version problems, where the asset in review no longer matches the references or the current label. Each of these is predictable, which means each can be checked before submission.
How to make MLR review faster without lowering the bar
Start from approved claims. When the brief specifies claims from a maintained claims library, each with its reference and its rules for use, the reviewer is checking how a known claim is used rather than evaluating a new one. This is the core idea behind modular content, and it is the single largest lever on review time.
Write the review questions into the brief and the template. If every email template already has a fixed place for the safety information, a reviewer never has to send one back for missing it. If the brief names the audience and channel, the reviewer never has to guess which rules apply.
Annotate before you submit. Every claim should arrive linked to its support, with the exact passage highlighted. Give agencies and content teams the same checklist the reviewers use, so the obvious issues are caught by the people who can fix them fastest.
Submit smaller and sooner. Large packets of assets reviewed together tend to fail together. Smaller, more frequent submissions keep feedback fast and make patterns easier to spot. Finally, agree review tiers with your MLR team in writing: a reuse of approved content in an approved context should not need the same depth of review as a new claim, and a documented process lets reviewers apply that difference with confidence.
Where AI fits in MLR review, and where it does not
AI does not approve promotional content, and it should not. Approval is a judgment that carries regulatory and legal accountability, and it belongs to qualified people. Any tool that blurs that line will, rightly, never get through a quality review.
Where AI helps is everything before the reviewer: drafting content only from approved claims and sources, linking every claim to its reference, checking content against the label for its market, flagging missing safety information, and keeping a record of where every line came from. These are the things that decide whether an asset passes on its first round.
This is how Magic Studio is built. It writes from your approved dossiers and Claims Library, cites every claim to its source, checks each one against the label for its market, places fair balance and safety information in the asset, and sends finished work into your MLR review queue and on into Veeva PromoMats. Your reviewers still decide. They just see fewer avoidable problems.
Frequently asked questions
What is the difference between MLR and PRC?
Usually none in practice. MLR names the three functions that review promotional content (medical, legal and regulatory), while PRC, or promotional review committee, names the group itself. Some companies use one term, some the other, and some include additional functions such as compliance or market access in the committee.
Who is on an MLR review team?
A medical reviewer, a legal reviewer and a regulatory reviewer, supported by the brand or content owner who submits the asset, the agency that produces it, and often an MLR coordinator who manages the queue and records. Some companies add compliance, market access or a medical information representative.
Does MLR review apply to medical affairs content?
Promotional content goes through MLR or PRC review. Non-promotional scientific content from medical affairs is usually reviewed through a separate medical review process, because it follows different rules and must stay separate from promotion.
What is a first-pass approval rate?
It is the share of assets approved, with or without minor changes, in their first round of MLR review. It is the most useful single measure of review efficiency, because the number of rounds, not the time spent in each, drives total review time.
Can AI replace MLR reviewers?
No. Approval carries regulatory and legal accountability and belongs to qualified reviewers. AI is useful before review: drafting from approved claims, linking references, checking content against the label and flagging missing safety information, so assets arrive ready to pass.